AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2218871 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette-Guerin plus cyclophosphamide, methotrexate, 5-fluorouracil, and tamoxifen
Number of subjects: 311
Study 6157258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol (80 microgram/d) and chlormadinonacetate
Number of subjects: 12
Study 31209595 — intervention group
Group type: COMPARATOR
Intervention: Any anticoagulant use
Number of subjects: 75336
Study 31209595 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 75336
Study 31209595 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparins (LMWH)
Number of subjects: 75336
Study 31209595 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant non-users
Number of subjects: 75336
Study 28358236 — intervention group
Group type: EXPERIMENTAL
Intervention: Better distress tolerance
Number of subjects: 117
Study 28358236 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower experiential avoidance
Number of subjects: 117
Study 28358236 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential avoidance (when both predictors examined simultaneously)
Number of subjects: 117
Study 25964404 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend-only recreational drug use
Number of subjects: 483
Study 24888316 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtle fruit syrup (15 ml daily for 7 days)
Number of subjects: 30
Study 24888316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22696989 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma 3 nail
Number of subjects: 112
Study 22696989 — intervention group
Group type: COMPARATOR
Intervention: ACE trochanteric nail
Number of subjects: 112
Study 22696989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 112
Study 19404189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 35
Study 19404189 — intervention group
Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 35
Study 17571966 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat grass juice (WGJ) 60 cc orally daily during the first three cycles of chemotherapy
Number of subjects: 60
Study 15965796 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patients
Number of subjects: 129681
Study 15965796 — intervention group
Group type: COMPARATOR
Intervention: Patients from nursing care units
Number of subjects: 129681
Study 11836778 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentation method combining expectation‐maximization (EM) tissue segmentation, template‐driven segmentation (TDS), and partial volume effect correction (PVEC)
Number of subjects: 30
Study 11836778 — intervention group
Group type: COMPARATOR
Intervention: Radiologist outlines of WMSA
Number of subjects: 30
Study 10404794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroidism
Number of subjects: 42
Study 10404794 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of euthyroidism
Number of subjects: 42
Study 10404794 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 42
Study 10404794 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperthyroidism
Number of subjects: 42
Study 8790827 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of flunisolide nasal spray
Number of subjects: 216
Study 8790827 — intervention group
Group type: EXPERIMENTAL
Intervention: Original formulation of flunisolide nasal spray
Number of subjects: 216
Study 8790827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 216
Study 1617763 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg alteplase (rt-PA)
Number of subjects: 1088
Study 1617763 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PTCA
Number of subjects: 1088
Study 1617763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study 1617763 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase, heparin, and aspirin
Number of subjects: 1088
Study 1617763 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine immediate PTCA
Number of subjects: 1088
Study 1617763 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary anatomy, left ventricular function, age, and previous infarction
Number of subjects: 1088
Study 6147213 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic CRF-41 100 micrograms
Number of subjects: 6
Study 6147213 — intervention group
Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 6
Study 31003961 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilation for 0 seconds
Number of subjects: 1920
Study 31003961 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation for 30 seconds
Number of subjects: 1920
Study 31003961 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation for 60 seconds
Number of subjects: 1920
Study 31003961 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation for 180 seconds
Number of subjects: 1920
Study 31003961 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation for 300 seconds
Number of subjects: 1920
Study 31003961 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 1920
Study 29496259 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotless barbed suture
Number of subjects: 102
Study 29496259 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture
Number of subjects: 102
Study 26028346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1347
Study 26028346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1347
Study 26028346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Ranibizumab and Bevacizumab)
Number of subjects: 1347
Study 23842831 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 178
Study 23842831 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme (SEP)
Number of subjects: 178
Study 23842831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (PTA + SEP)
Number of subjects: 178
Study 21436463 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude exposure (5,400 m) for 2 weeks
Number of subjects: 33
Study 19103434 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (2400 mg daily) for 4 weeks
Number of subjects: 0
Study 19103434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19103434 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine self-administration or osmotic minipumps
Number of subjects: 0
Study 17763261 — intervention group
Group type: EXPERIMENTAL
Intervention: 1EV/2DNG
Number of subjects: 98
Study 17763261 — intervention group
Group type: COMPARATOR
Intervention: E2/NETA
Number of subjects: 98
Study 17763261 — intervention group
Group type: EXPERIMENTAL
Intervention: 1EV/2DNG/E2/NETA
Number of subjects: 98
Study 15270927 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postnatal discharge combined with home midwifery support (n=228)
Number of subjects: 459
Study 15270927 — intervention group
Group type: COMPARATOR
Intervention: Traditional postnatal hospital stay (n=231)
Number of subjects: 459
Study 11442521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 5456
Study 7951614 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptoreline (Décapeptyl* 3.75 mg)
Number of subjects: 198
Study 7951614 — intervention group
Group type: EXPERIMENTAL
Intervention: Gosereline (Zoladex*)
Number of subjects: 198
Study 7951614 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuproreline (Enantone* 3.75 mg)
Number of subjects: 198
Study 3519227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 52
Study 3519227 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 31757648 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive anti-phospholipid antibodies (aPLs)
Number of subjects: 1712
Study 31757648 — intervention group
Group type: EXPERIMENTAL
Intervention: aGPI IgA
Number of subjects: 1712
Study 31757648 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive history of cardiovascular events
Number of subjects: 1712
Study 31757648 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral obliterans arterial vasculopathy
Number of subjects: 1712
Study 31757648 — intervention group
Group type: EXPERIMENTAL
Intervention: aPL positivity among high CV risk subjects (Framingham risk score >20, diabetes, BMI >35 kg/m2)
Number of subjects: 1712
Study 29782435 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled tub bath
Number of subjects: 43
Study 29782435 — intervention group
Group type: COMPARATOR
Intervention: Conventional tub bath
Number of subjects: 43
Study 27323753 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT)
Number of subjects: 608
Study 27323753 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 608
Study 24825371 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak patients
Number of subjects: 227
Study 24825371 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak patients with persistent weakness
Number of subjects: 227
Study 23783292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified milk and bread
Number of subjects: 782
Study 23783292 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified milk and bread (Control)
Number of subjects: 782
Study 20598488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Alcohol Syndrome (FAS)
Number of subjects: 51
Study 20598488 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with PEA
Number of subjects: 51
Study 20598488 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol-exposed children (NC)
Number of subjects: 51
Study 17681110 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain stimuli
Number of subjects: 44
Study 17681110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic pain stimuli
Number of subjects: 44
Study 17681110 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-onset muscle pain stimuli
Number of subjects: 44
Study 16386942 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation, 1000 microg/day during 1 week (n=30)
Number of subjects: 99
Study 16386942 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (800 microg/day), B12 (20 microg/day), and B6 (4 mg/day) during 1 week (n=29)
Number of subjects: 99
Study 16386942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 14691345 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 32
Study 14691345 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 32
Study 14691345 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 32
Study 10771231 — intervention group
Group type: EXPERIMENTAL
Intervention: CeeOn model 911F (sharp optic edges)
Number of subjects: 50
Study 10771231 — intervention group
Group type: COMPARATOR
Intervention: CeeOn model 920 (rounded optic edges)
Number of subjects: 50
Study 8610709 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 203
Study 8610709 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-administered diet history
Number of subjects: 203
Study 1731544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75
Study 1731544 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 75
Study 3530769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg X 3 daily
Number of subjects: 2279
Study 28716693 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy combined with reflexology
Number of subjects: 40
Study 28716693 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental therapy alone
Number of subjects: 40
Study 25737426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic walking
Number of subjects: 179
Study 25737426 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aerobic flexibility, toning, and balance
Number of subjects: 179
Study 25737426 — intervention group
Group type: COMPARATOR
Intervention: Both groups (aerobic walking and non-aerobic flexibility)
Number of subjects: 179
Study 25002241 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 56
Study 25002241 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 56
Study 22474202 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 with cetuximab
Number of subjects: 2686
Study 22474202 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 alone
Number of subjects: 2686
Study 21784327 — intervention group
Group type: EXPERIMENTAL
Intervention: Plumbum metallicum 15 cH, orally for 35 days
Number of subjects: 131
Study 21784327 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally for 35 days
Number of subjects: 131
Study 18926844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt Illusion (TI) with briefly flashed context
Number of subjects: 0
Study 18926844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt Illusion (TI) with simultaneous context and inducer
Number of subjects: 0
Study 18926844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rod and Frame Illusion (RFI) with visible frame for at least 800 ms
Number of subjects: 0
Study 18926844 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of illusion magnitude and discriminability
Number of subjects: 0
Study 16308341 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (MTX)
Number of subjects: 271
Study 15623951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg once weekly for 12 months with topical ketoconazole cream
Number of subjects: 121
Study 15623951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg once weekly for 12 months with topical ketoconazole cream
Number of subjects: 121
Study 15623951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg once weekly for 12 months with topical ketoconazole cream
Number of subjects: 121
Study 11273142 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50 mg
Number of subjects: 145
Study 11273142 — intervention group
Group type: COMPARATOR
Intervention: Enalapril maleate 5 mg
Number of subjects: 145
Study 9377073 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (CY) in study I
Number of subjects: 19
Study 9377073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) + TBI (200 mg/kg) + antithymocyte globulin (ATG) in study II
Number of subjects: 19
Study 9377073 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group from study I)
Number of subjects: 19
Study 9377073 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison between unrelated donor marrow and HLA-matched sibling donors)
Number of subjects: 19
Study 9377073 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison of engraftment rates)
Number of subjects: 19
Study 8259754 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy (Estraderm 50 micrograms/24h)
Number of subjects: 242
Study 8259754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 3853581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 10 mg BID
Number of subjects: 12
Study 3853581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin 20 mg BID
Number of subjects: 12
Study 3853581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevinolin (both doses)
Number of subjects: 12
Study 3853581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28856592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education and ultrasonic baths for denture cleaning (n=144)
Number of subjects: 219
Study 28856592 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 219
Study 26790579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 351
Study 26790579 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 351
Study 26790579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 25314063 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 162
Study 25314063 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (observation)
Number of subjects: 162
Study 22366894 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion at 15º/s for 20 min
Number of subjects: 16
Study 22366894 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive motion at 0º/s for 20 min (control)
Number of subjects: 16
Study 19730448 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior continuous curvilinear capsulorhexis (PCCC)
Number of subjects: 20
Study 19730448 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eye without PCCC)
Number of subjects: 20
Study 18388088 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg/d increasing to 10 mg
Number of subjects: 86
Study 18388088 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 600 mg/d increasing to 600 mg twice a day
Number of subjects: 86
Study 18388088 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/d and indapamide 2.5 mg/d, increasing amlodipine to 10 mg/d
Number of subjects: 86
Study 18388088 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg/d and indapamide 2.5 mg/d, imidapril doubled to 20 mg/d
Number of subjects: 86
Study 16018157 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 20
Study 16018157 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 20
Study 12453815 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based program to prevent drug use initiation
Number of subjects: 0
Study 12453815 — intervention group
Group type: COMPARATOR
Intervention: Control area (no intervention)
Number of subjects: 0
Study 12453815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention activities in schools
Number of subjects: 0
Study 10901689 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary and Self-Instructional Training (DSIT)
Number of subjects: 0
Study 10901689 — intervention group
Group type: COMPARATOR
Intervention: Diary Only (DO)
Number of subjects: 0
Study 7492156 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (n = 24)
Number of subjects: 45
Study 7492156 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (n = 21)
Number of subjects: 45
Study 1789815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg q.p.m. for group I, 40 mg q.p.m. for group II)
Number of subjects: 182
Study 1789815 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (600 mg b.i.d.)
Number of subjects: 182
Study 6216621 — intervention group
Group type: EXPERIMENTAL
Intervention: Woven Dacron grafts (USCI, DeBakey, C. R. Bard, Inc.)
Number of subjects: 24
Study 6216621 — intervention group
Group type: EXPERIMENTAL
Intervention: Knitted Dacron grafts (Microvel, Meadox Medicals, Inc.)
Number of subjects: 24
Study 31066510 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP)
Number of subjects: 0
Study 28821950 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC110
Number of subjects: 32
Study 28821950 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC80
Number of subjects: 32
Study 28821950 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 26026121 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel (36 mg/m2, days 1 and 8)
Number of subjects: 52
Study 26026121 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (36 mg/m2, days 1 and 8) plus oxaliplatin (80 mg/m2, day 1)
Number of subjects: 52
Study 24814697 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 34
Study 24814697 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 34
Study 21081539 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with diabetes educator every 4-6 weeks and pedometer use
Number of subjects: 1650
Study 21081539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer use
Number of subjects: 1650
Study 21081539 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1650
Study 19750572 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy
Number of subjects: 4133
Study 19750572 — intervention group
Group type: COMPARATOR
Intervention: Conventional antacid therapy (non-eradication group)
Number of subjects: 4133
Study 19750572 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication therapy
Number of subjects: 4133
Study 19750572 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 4133
Study 16356598 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate (PCV7) vaccine administered concurrently with DTaP.IPV/Hib and hepatitis B vaccines
Number of subjects: 368
Study 16356598 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate (PCV7) vaccine administered sequentially with DTaP.IPV/Hib and hepatitis B vaccines
Number of subjects: 368
Study 15051188 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 42
Study 15051188 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 42
Study 15051188 — intervention group
Group type: COMPARATOR
Intervention: Patients with eating disorder (ED)
Number of subjects: 42
Study 11772282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone 0.5 mg/day
Number of subjects: 96
Study 11772282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone 0.25 mg/day
Number of subjects: 96
Study 11772282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone 0.1 mg/day
Number of subjects: 96
Study 11772282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone 0.05 mg/day
Number of subjects: 96
Study 11772282 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone acetate
Number of subjects: 96